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Resumo 
Cerca de 34,4 milhões de pessoas consumiram estimulantes do tipo anfetamina no último ano 
avaliado (2012), alertando para a alta prevalência deste grupo, sendo o segundo grupo de drogas 
mais consumido em vários países a seguir aos canabinóides. A metanfetamina é a droga de 
eleição neste grupo, sendo usada maioritariamente nos Estados Unidos da América, Norte e 
Centro da Europa e Sul/Sudeste da Ásia. Deste modo a problemática da dependência de 
metanfetamina gera grandes encargos sociais, económicos e de saúde pública nestes países. 
Contudo não há tratamento farmacológico específico e direcionado à dependência de 
metanfetamina e a evidência neste campo não é abundante comparando a outras drogas de 
abuso, tendo vindo a crescer recentemente. Nos últimos anos tem havido um maior foco no 
exercício físico como adjuvante na terapia de doentes dependentes de drogas de abuso, e 
estudos relativos à metanfetamina têm vindo a crescer em número. O presente trabalho pretende 
fornecer uma revisão de literatura relativamente ao estado atual do uso de metanfetamina e seu 
tratamento, e qual o possível papel do exercício físico na terapia destes doentes. Globalmente 
foram demonstradas melhorias significantes em indivíduos ativos, resultando em melhores 
parâmetros de capacidade física, baixas taxas de recidiva e abstinência mantida quando 
comparados a indivíduos que não praticam exercício físico, tanto em estudos com modelos 
animais como em estudos clínicos. Contudo mais estudos são desesperadamente necessários 
para confirmar reprodutibilidade destes achados: estabelecer o programa de exercício mais 
eficaz, atendendo ao sexo, idade e estado mental, nomeadamente em termos de duração, 
intensidade, tipo e necessidade de supervisão e determinar a associação mais favorável aos 
tratamentos atualmente disponíveis.  
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Abstract 
An estimated 34,4 million people has consumed amphetamine-type stimulants over the last 
evaluated year (2012), which alerts for the high prevalence of this drug group, being the second 
most abused drug group in several countries. Methamphetamine is the primary drug within 
amphetamine-type stimulants, being highly used in the United States of America, Central and 
Northern Europe and South/South-eastern Asia. Therefore, methamphetamine use disorder is 
understandably a major social, economic and healthcare issue among these countries; however 
there is no pharmacologic treatment addressed specifically to methamphetamine dependence, 
and overall evidence to specific treatment is not as abundant as with other drugs of abuse. 
Recently there has been emphasis on physical exercise as a conjoint therapy for drug abuse, and 
evidence is steadily increasing regarding methamphetamine. The present review pretends to 
provide an up-to-date overview of the current state of methamphetamine use and evidence on 
physical exercise and methamphetamine treatment. Overall, there were great improvements 
demonstrated in users, with better fitness measures, lower relapse rates and sustained abstinence 
when compared to non-exercised individuals, both in preclinical and clinical studies. However, 
further studies are profoundly needed, to confirm reproducibility of previous findings and to 
highlight the following parameters: establish the most efficient exercise program, attending to 
sex, age and mental consequences of chronic use, namely duration, intensity, type and need of 
supervision and association with current treatments. 
Keywords 
Physical exercise; amphetamine; methamphetamine; amphetamine-type stimulants; drug 
addiction and reward system 
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Introduction 
According to the United Nations Office on Drugs and Crime’s (UNODC) “World Drug Report 
2014” the market for Amphetamine-type stimulants (ATS) seems to be increasing, with an 
estimated 34,4 million people (between 0,3 and 1,3 per cent of the world’s population) having 
consumed these substances over the last evaluated year (2012), being the second most widely 
consumed drug group in many countries right after cannabis, as stated on the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol’s 2009 joint 
publication on methamphetamine. ATS seizures have increased 66 per cent from 2010 to 2011, 
from 74 tons up to 123 tons, and to 144 tons in 2012 (an increase of 15 per cent), the highest 
quantity ever noted. The largest slice of the ATS issue corresponds to the methamphetamine 
(METH) sales market (71 per cent of all seizures), partially due to the rather simple way of 
manufacturing the drug via clandestine drug labs and the fact that it is a synthetic compound 
with available chemical substances.  
There are two isomers of methamphetamine, which is part of the amphetamine (1-methyl-2-
phenylethylamine) type stimulants group: the L- (levorotatory) and the D- (dextrorotatory) 
forms. The D- form (also called the S- form) is the most biologically active, with the highest 
capability of stimulating the central nervous system (CNS) and being the widest spread, illicitly 
available form. METH exerts its effects by various means of action: acting as an indirect 
agonist, binding itself to dopamine, serotonin and noradrenaline transporters (respectively 
DAT, SERT and NET) in the cell membrane and also to the vesicular monoamine transporter 
2 (VMAT-2). By reversing the function of these transporters, METH manages to release great 
amounts of monoamines into the cytosol, while also decreasing their metabolism by inhibiting 
monoamine oxidase (1). 
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Being such a burden on the worldwide drug control, the management and treatment of METH-
dependent users is of great concern in today’s clinical practice. Currently the basis of the 
treatment relies on low-efficacy pharmacologic agents and cognitive-behavioural therapy and 
contingency management with variable success, as applied to other drug addictions such as 
alcohol and cocaine addiction. The aim of this review is to provide an up-to-date overview of a 
recent approach that has been applied to other drug dependencies (i.e. alcohol, cocaine) but 
only recently began to gain interest regarding methamphetamine use: physical exercise, either 
aerobic or anaerobic as a support for current treatment.  
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Methods 
Search for up-to-date literature was conducted mainly on PubMed (Medline®) and associated 
databases, and on the B-on (Biblioteca do Conhecimento Online) online database system of the 
University of Coimbra, mainly through Reuters’s Web of ScienceTM. Publications relevant to 
the subject were also widely consulted, namely those provided by the United Nations Office on 
Drug and Crime and European Monitoring Centre for Drugs and Drug Addiction. Preclinical 
and clinical trials (papers on exercise regimens and its influence on rat models and exercise 
programs on recovering drug-addicted users) as well as literature reviews on the matter were 
analysed. Research for literature was initiated on the first quadrimester of 2014. The following 
main keywords were used: “(physical exercise) and (amphetamine or methamphetamine)”, 
“(physical exercise) and (drug addiction)” and “amphetamine-type stimulants”. Additional 
keywords were vital to the scope of this work:  “(exercise) and (drug abuse)”, 
“(methamphetamine) and (exercise)” and “reward system”. Relevant references of the searched 
articles were also included in the overall search criteria. 
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Results 
1. Global Prevalence of Methamphetamine   
According to the UNODC, in 2006 there were an estimated 14 million amphetamine users 
worldwide; in 2012 the best possible estimate is 34 million users (2). In fact, ATS are the second 
most abused group of drugs in the world after cannabinoids and followed by opioids and 
opiates, with METH being the main drug within the group. METH consumption and trafficking 
has been increasing for the last decade. Although, for the last few years the prevalence of METH 
has remained somewhat stable (figure 1).  
 
 
 
 
 
 
 
 
The same report states that more than 12 571 laboratories were dismantled in 2011, whereas in 
2012 this number increased to 14 322. The vast majority of these labs were synthetizing 
methamphetamine (96 per cent). This tendency also reflects itself on the number of 
methamphetamine seizures (figure 2): from 24 tons in 2008 to 114 tons in 2012 (from a total of 
144 tons).  
Figure 1: Prevalence of methamphetamine use and treatment admissions for the past few years. 
Prevalence of METH use remains stable. Adapted from UNODC’s World Drug Report 2014 (2). 
9 
 
 
 
 
By analysing the quantity seized by region, it is clear that North America is the one with the 
highest amount seized (64 per cent), followed by Eastern and South-eastern Asia (around 33 
per cent). By country, the top three consists in Mexico, the United States of America and China, 
by this order.  
This problematic is worsened by an ever-increasing number of organized laboratories, the super 
labs (built by organized crime societies, such as drug cartels in Mexico) which manufacture the 
majority of the drug (85 per cent in the United States only), and many small ones, home labs, 
the so called “Mom and Pop labs”, which in turn can be found virtually anywhere, from 
domestic households, vehicles and garages to hotel rooms, public restrooms and recreational 
vehicles (3). This can be seen as a public health issue, since the toxic compounds and chemical 
waste is all in all very hazardous to human health: fumes, vapours and spills due to the 
manufacture process, drug paraphernalia (pipes, spoons, needles, syringes and masks), contact 
with the skin leading to severe chemical burns, contaminated objects and inadvertent ingestion. 
Also, approximately 15 per cent of meth labs are discovered due to explosions and fires, due 
mainly to careless handling and overheating of the chemical compounds. Intimately associated 
with household meth labs are poor health conditions, where filth and garbage abound. 
Figure 2: Global seizures of ATS from 2003 to 2012. Methamphetamine, besides being the main drug 
from the group, shows a rapid growth through the years. Adapted from  UNODC’s World Drug Report 
2014 (2). 
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Ultimately there are several social issues surrounding an environment where a member of the 
family or the entire family manages to produce METH, especially when children are involved, 
as this brings along an array of complications, both physical and psychological, to the normal 
growth of the child (4).  
On a closer note, METH use and addiction in Europe is a lot lower in comparison to North 
America and Asia. It is the third most consumed synthetic drug after amphetamine and 
“ecstasy”, corresponding to less than 13 per cent of the all ATS seizures (5). Still, it follows the 
same trend within other regions, as it is slowly expanding during the last decade (6). The best 
estimates available, as of 2014, point to 2,8 million users in Europe as a whole, with almost 70 
per cent represented by Western and Central Europe (1,95 million) (2). Czech Republic and 
Slovakia present the highest prevalence of METH abuse according to available data, which 
reveal that demand for treatment is increasing in those countries (61 per cent of all drug 
treatment patients in Czech Republic report it as the primary drug of abuse whereas in Slovakia 
it is 26 per cent). Available data is sparse in Europe, with few reports differentiating between 
amphetamine and methamphetamine in terms of prevalence (figure 3). Although, the 
EMCDDA 2010 report shows that of a total of 302 kg of METH seized in total only in Europe, 
the top 6 countries are either Nordic or Central and Baltic countries: Norway (34 per cent), 
Sweden (25 per cent), Estonia (12 per cent), Latvia (11 per cent), Lithuania (9 per cent), Finland 
(6 per cent). Czech Republic has a reported high prevalence of METH users and number of 
labs, but the amount seized corresponds only to 1 per cent of the total.  
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In Portugal the first dismantlement of a METH lab occurred in 2007, in Viana do Castelo; 
another piece of news reported a dismantled lab in Terceira Island from the Azores archipelago 
in 2012 making these the only known METH labs in Portuguese territory so far. The prevalence 
of amphetamine abuse is rather low (there is no evaluation on METH abuse alone), according 
to the 3rd National Inquiry on the use of psychoactive substances from 2012 (7): on the general 
population (from 15 to 64 years old) such lifetime prevalence was 0,5 per cent, increasing to 
0,6 per cent in the sub group of 15 to 34 years old. Highest prevalence was noted on Lisbon, 
Alentejo and Algarve. Altogether, the lifetime prevalence decreased from 2007 to 2012 (0,9 per 
cent to 0,5 per cent) on the general population, being higher on men. Another study, the ESPAD 
2011 (European School Survey Project on Alcohol and other Drugs) shows higher prevalence 
in the young population, with lifetime prevalence of 3 per cent. Also on this age bracket the 
Portuguese ECATD 2011 (Study on the Use of Alcohol, Tobacco and Drugs) reports an 
amphetamine use prevalence between 1.1 to 3.5 per cent. 
Figure 3: Prevalence of methamphetamine use on young adults (15 to 34 years old). Highest 
prevalence is mainly found on Central and Northern Europe. Adapted from EMCDDA’s Selected 
Issue 2010 on the Amphetamine and Methamphetamine use in Europe (6). 
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2. Molecular and Pharmacological Aspects of Methamphetamine  
Methamphetamine takes part in a larger group known as “amphetamine-type stimulants” which 
comprises both “amphetamines” such as amphetamine, methcathinone, fenetylline, ephedrine, 
pseudoephedrine, methylphenidate and methamphetamine and “ecstasy-type drugs” namely 
MDMA (3,4-methylenedioxy-methamphetamine) commonly known as “ecstasy”, MDA (3,4-
methylenedioxyamphetamine) and MDEA (3,4-methylenedioxy-N-ethylamphetamine). The 
later subgroup is characterized by having hallucinogenic properties (6). Amphetamines are a 
group of drugs derived from phenylethylamines, with an identical chemical structure to that of 
dopamine (figure 4). Phenylethylamines are naturally present in the human body acting as a 
stimulant of the central nervous system, and are synthetized from the amino acid phenylalanine 
(8). Amphetamines are therefore the methyl derivative of phenylethylamines, sharing the same 
stimulant properties. METH in turn is the N-methyl derivative of amphetamine, and can exist 
as one of two isomers: the L- (levorotatory) and D- (dextrorotatory) forms, with D-
methamphetamine being the one with highest capacity of stimulating the CNS (up to 3-5 times 
the activity comparing with the L- form (9)). A popular term for a particular kind of METH is 
“ice” or “crystal meth”, describing the hydrochloride of the D-form (10).  
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Being a cationic lipophilic molecule, METH is capable of better penetration in the CNS 
compared to amphetamine, which results in stronger stimulation (11). METH acts as an indirect 
agonist of dopamine, noradrenaline and serotonin receptors  reversing their function and 
inducing the release of these monoamines and blocking their reuptake in the synaptic cleft (1). 
Methamphetamine binds to the dopamine transporter (DAT), noradrenaline transporter (NET), 
serotonin transporter (SERT) and vesicular monoamine transporter-2 (VMAT-2). The final 
outcome consists in vesicles containing monoamines being emptied into the cytosol thus 
releasing them into the synaptic cleft and thereby stimulating postsynaptic receptors. In order, 
norepinephrine and dopamine are more efficiently released than serotonin (12).  
To a lesser extent METH also inhibits monoamine oxidase, diminishing their metabolism (10). 
While VMAT-2, DAT, NET and SERT are integral membrane proteins, the former (VMAT-2) 
is the only capable of recognizing and transporting all amine neurotransmitters, while the others 
are selective for the respective amine. Also, VMAT-2 is part of vesicular membranes, while the 
others are plasma membrane transporters; its function is to transport and store monoamine 
Figure 4: Similarities in the structure of a monoamine (dopamine) and the Amphetamine-type 
stimulants (amphetamine, methamphetamine and MDMA – “ecstasy”). Adapted from Fleckenstein et 
al (69). 
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neurotransmitters (dopamine, noradrenaline and serotonin) in vesicles within the neurons to be 
posteriorly released onto the synaptic cleft (12).  
The selective transporters retrieve monoamine neurotransmitters from the synapse into the 
neuronal cytosol, attenuating their action in the postsynaptic receptors. METH seems to take 
effect mainly on the dopaminergic system; therefore, by stimulating the release of dopamine 
into the synapse, METH acts on the major CNS dopaminergic circuitry: the mesolimbic, 
mesocortical and the nigrostriatal pathways, which take a huge part on the dependency 
pathways for drug abusers (1,13). Each one is responsible for specific actions and reactions of 
the individual, as described in the comprehensive review by Hsieh, Stein and Howells (14): 
mesolimbic circuit acts in reward processing, effort related functions and translation of 
emotions into actions; mesocortical circuit intervenes in cognitive functions namely working 
memory and the nigrostriatal pathway is involved in the control of expression and direction of 
behaviour to predictable stimulus or reward. Positive reinforcing effects stem from the 
activation of the ventral tegmental area of the midbrain dopamine system and the prefrontal 
cortex and limbic regions (including the nucleus accumbens), which in turn are capable of 
inducing addictive habits (9).  
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3. Methamphetamine: Clinical Pharmacokinetics, Pharmacodynamics 
and Toxicodynamics 
Being a synthetic drug, METH can be produced by using various chemical compounds and 
“cooking” them (the street term for the process of manufacturing METH). A myriad of names 
can be used to describe METH on the streets and illegal market: speed, crank, meth, crystal 
meth, ice (in the U.S.A.), Pervitin (Czech Republic), yaba and shabu (Far East). There is a 
myriad of routes of administration; according to the National Institute on Drug Abuse, the most 
common method is by smoking (inhaling the fumes after heating the hydrochloride form) 
providing a quick absorption and access to the CNS where it will exert its effects. This route of 
administration has the highest bioavailability following injecting.  Despite of smoking being 
the most common, method of use varies by region. There are several other ways of 
consumption, either by dissolving the hydrochloride form in water and thus injecting it or by 
“snorting” and ingesting methamphetamine in powder form, where it is absorbed by the mucous 
membranes, including rectally and sublingually (8).  
METH is extensively metabolized in the liver via phase I reactions mediated by cytochrome 
p450 2D6 (1,10): N-demethylation produces amphetamine; aromatic hydroxylation produces 
4-hydroxymethamphetamine and finally β-hydroxylation produces norephedrine, among other 
metabolites (e.g. hippuric acid) that have little influence on the clinical spectrum. Regarding 
phase II reactions, N-acetylation and other conjugation reactions occur. Afterwards the kidneys 
eliminate some 30 to 50 per cent as non-metabolized METH, while the rest corresponds to the 
various metabolites, and the kidneys eliminate 70 per cent of a single oral dose during the first 
24 hours. 
Being a stimulant drug of the CNS, methamphetamine shares its effects with other stimulant 
drugs, both inside the group of ATS and out (such as cocaine). The clinical presentation is 
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dominated by signs and symptoms translating a sympathetic response by the autonomous 
nervous system (tachycardia, tachypnea, hypertension, pupil dilation, hyperthermia, reduced 
fatigue) and by a state of euphoria and social ease of relating with other people, increased 
attention, behavioural disinhibition, reduced appetite, and sense of increased energy, sex drive 
and self-confidence (10,15). Repeated abuse of methamphetamine (sometimes every few hours 
- called “binging”, also when referring to other substances, as alcohol) results in mental 
disturbance, from insomnia, an aggressive state and depressive mood to severe psychiatric 
conditions such as methamphetamine-induced psychosis, comparable to acute episodes of 
schizophrenia, where users relate delusions (persecutory, reference, mind-reading), 
hallucinations (mainly auditory, also visual and tactile) and odd speech (1,10). Understandably, 
METH can lead to serious cardiovascular (e.g. arrhythmia, acute coronary syndrome, sudden 
cardiac death and aortic dissection) and systemic conditions (e.g. bruxism, tremor) such as the 
so-called “meth mouth”, with severe teeth decay (16).   
As with other drugs of abuse, sudden cessation of methamphetamine causes a withdrawal 
syndrome presenting as anhedonia, irritable or aggressive mood, sleep disturbance, diminished 
cognitive functions, anxiety and craving and musculoskeletal pain among other signs and 
symptoms, with depressive symptoms being characteristic of this drug’s withdrawal syndrome 
(10,17). This may be caused by depleted monoamine reserves which were storing monoamines 
before beginning of abuse, down regulation of receptors and overall neurotoxicity (1). In fact, 
long-lasting abuse of amphetamines leads to down-regulation of D1 (expressed in the 
striatonigral neurons) and D2 (expressed in striatopallidal neurons) dopamine receptors causing 
an imbalance of this neurotransmitter as observed in several studies before (18). METH users 
have reduced dopamine and serotonin axonal markers, decreased striatal dopamine transporter 
density and damaged dopamine nerve terminals. The levels of various metabolites related with 
neuronal viability are decreased, due to neurotoxicity, namely n-acetyl-aspartate and ratio of 
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this metabolite to creatine. On the other hand, concentration of choline metabolites is higher in 
frontal regions and in the basal ganglia (19). Dopaminergic terminals located in the ventrolateral 
caudate nucleus and putamen are the most damaged, while those located in the dorsolateral 
caudate nucleus and putamen are the least harmed, and those located in the nucleus accumbens 
are mostly spared (20). Additionally, neuronal lesion takes place primarily in the axonal and 
terminal (telodendria) parts; although the precise mechanism of toxicity has not been 
completely understood. However a possible mechanism is oxidation of dopamine and serotonin 
into 6-hydroxydopamine and 5,6-dihydroxytryptamine, which in turn can oxidize proteins, 
nucleic acids and lipids in neurons where these neurotransmitters abound (1). Amphetamine 
causes the build-up of dopamine, which when in excess is then prone to oxidation and originates 
dopamine-quinones therefore damaging macromolecules (21). There is also evidence of lower 
perfusion to the brain tissue and decreased levels of SERT in cortical and subcortical (including 
the striatum – caudate nucleus and putamen), DAT and VMAT-2 in the striatum in abstinence 
users (14,19).  
Glial cells are also damaged in METH use disorder. For example, it was demonstrated that daily 
methamphetamine use decreases oligodendrocytes and astrocytes in the prefrontal cortex of 
laboratory rats as a consequence of a decrease in gliogenesis; this reduction was associated with 
methamphetamine intake (22). However, METH acutely increased gliogenesis in prefrontal 
cortex (22). Regarding brain structural changes, METH users seem to have smaller grey-matter 
volume on the cortex (frontal, occipital, temporal and insular lobes) but larger on the striatum; 
following 3 to 4 months of abstinence, grey-matter volume is higher in several regions of the 
CNS (parietal cortex, caudate nucleus, nucleus accumbens and lenticular nucleus - putamen and 
globus pallidus) than in non-users (19).  
These cellular, neurochemical and structural changes might translate into neurological and 
psychiatric changes. In fact, chronic methamphetamine users show a decline at a cognitive 
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level, with impaired episodic memory, executive functions (such as problem solving), complex 
information processing speed and psychomotor functions; this impairment is potentially 
reversed with sustained abstinence (10,19). These cognitive findings are rather relevant, as the 
cognitive assessment is a phenomenal aid when choosing optimal treatment for each case, so 
much so that users with impaired cognitive functions are less prone to maintain a sustained 
treatment and become less engaged in the process (18). 
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4. Addiction and Reward 
Early theories to explain addiction reside in reinforcement principles and conditioning, namely 
positive reinforcement, ultimately leading to repeated use of a substance and negative 
reinforcement, as observed with the withdrawal syndrome. Each drug class activates specific 
receptors or acts in a specific way, often sharing their effects in the CNS as seen with 
amphetamines and cocaine for instance, both acting in monoamine transporters and their 
concentration in the synapse. Regarding psychostimulants, their action in the DAT by inhibiting 
the dopamine reuptake in the nucleus accumbens seems to be the main mechanism responsible 
for positive reinforcement seen in these users (23). Physical exercise acts in several of the same 
pathways that constitute addiction and reward neurobiology, as posteriorly developed. 
 
As briefly described earlier, the mesocorticolimbic and nigrostriatal system are deeply involved 
in reward and consequently addiction (24). Dopaminergic pathways encompass the following 
routes: from the ventral tegmental area (VTA) of the midbrain to the limbic system, primarily 
Figure 5: The dopaminergic system. Dopaminergic neurons from the mesencephalon head to 
cortices (specially, prefrontal cortex) (blue), the nucleus accumbens (green) and the striatum 
(red). VTA: ventral tegmental area; SNc: substantia nigra pars compacta. Adapted from Arias-
Carrión O et al (25) 
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Figure 6: Reward pathways in the brain of the laboratory rat and sites of drug action. Dopaminergic, 
GABAergic, glutamatergic and opioid circuits are shown.  
Blue area: nucleus accumbens; Red area: ventral tegmental area; Green area: frontal cortex (FCX) and olfactory tubercle (OFT); 
ABN: anterior bed nuclei of the medial forebrain bundle; AMYG: amygdala; BNST: bed nucleus of the stria terminalis; BSR: 
brain-stimulation reward; CRF: corticotropin releasing factor; DA: dopamine; DYN: dynorphin; END: endorphin; ENK: 
enkephalin; GABA: gamma-aminobutyric acid; GLU: glutamate; HIPP: hippocampus; 5HT: serotonin; HYPOTHAL: 
hypothalamus; LAT-TEG: lateral tegmental noradrenergic cell groups; LC: locus coeruleus; NE: norepinephrine; OPIOID: 
opioid peptides; PAG: periaqueductal grey matter; Raphe: raphe nuclei; RETIC: reticular formation of the brain stem; VP: 
ventral pallidum. Adapted from Gardner E. L. (67) 
 
to the nucleus accumbens (mesolimbic); from the VTA to the cortices, namely the prefrontal, 
cingulate and perirhinal (mesocortical) and from the pars compacta of the substantia nigra 
(nigrostriatal), as summarized in figure 5. Besides reward, these dopaminergic pathways play a 
predominant role on craving and relapse. These neurons have several types of dopamine 
receptors, grouped in two families, the D1-like receptors, comprising D1 and D5 (which 
activate the enzyme adenylyl cyclase) and the D2-like receptors, namely D2, D3 and D4 
receptors (which in turn inhibit this enzyme). D1-like receptors are mainly found in the 
prefrontal cortex, while D2-like receptors are mostly found in the striatum and nucleus 
accumbens (25). Other mechanisms and neurotransmitters also take a part on the reinforcement 
effects of drug addiction: GABA, opioid peptides (such as endorphins) and glutamate all 
contribute to this process (figure 6).  
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5. Current Management and Treatment of Acute Use 
Up until now, there are limited options for the treatment of methamphetamine use disorder, 
with low efficacy and high relapsing rates. Stimulant use disorder (where methamphetamine 
abuse is included), as defined by the DSM-5 (figure 7) consists in several items which are put 
together to translate a mild, moderate or severe abuse (the term abuse was exchanged for the 
less demeaning word use on the new edition). Treatment can be directed to acute syndromes 
and chronic use/dependence. The purpose of this review is to focus on the chronic form of 
METH use disorder; therefore acute treatment will only be reviewed briefly. In many ways 
methamphetamine-related diseases are treated the same way as other causes (for instance 
cardiovascular consequences) despite the increasing number of emergency room visits (26). 
Acute intoxication can be managed using supportive measures most of the times (according to 
severity of the patient’s state of presentation), either by “talking down”, where the doctor calms 
down the patient by talking to him in a quiet environment or by taking a more direct approach 
using sedatives, namely an anxiolytic (benzodiazepine) or a strong antipsychotic drug when 
facing aggressive or paranoid patients. Drugs of choice should be midazolam, a benzodiazepine 
with higher sedative than anxiolytic power or other drug from the same group (such as 
lorazepam or diazepam) and haloperidol or droperidol (both butyrophenones), as there are no 
significant differences in need for repeat of sedation and adverse effects between the two (27). 
Newer atypical antipsychotics can also be used instead of haloperidol, namely olanzapine and 
ziprasidone (26). 
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Figure 7: Diagnostic criteria for stimulant use disorder.  
Mild: 2 to 3 symptoms. Moderate: 4 to 5 symptoms. Severe: ≥ 6 symptoms.  
Adapted from Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (70). 
 
  
  
 
 
 
 
 
23 
 
6. Methamphetamine Dependence Management 
6.1 General Considerations 
There are rather aggravating problems concerning the treatment of METH use disorder. The 
overall costs are too high in some aspects, as the need of specialized personnel and 
infrastructures, along with the necessity of a continued monitoring and follow-up of these 
patients, as a short-term strategy is not usually ideal (28).  
Significant differences between user groups need to be taken into account: users who initiate 
drug use later tend to start treatment before earlier users and are also less inclined to inject 
METH; simultaneous abuse of other drugs also contributes to low-treatment compliance and is 
seen mainly on early onset use, which demand particular care (29). The authors of this same 
study state that probably a high level of treatment early on is essential to decrease use in 
moderate to heavy users, and overall treatment should be started as early as possible with 
positive outcomes. Gender also plays a determinant role in drug abuse. A study by Hser et al 
noticed that in a population of 1073 METH abusers (both men and women) from California 
women had more severe issues, as unemployment and mental diseases than men, ultimately 
leading to serious challenges during treatment, despite showing greater improvement (30). 
Aggravatingly, amphetamine’s withdrawal syndrome is a predominant factor to take into 
consideration, usually happening within 24 hours of sudden cessation of drug use (31). As 
described before, it consists in severe depressive symptoms, such as long-lasting anhedonia, 
dysphoria and craving (28). Methamphetamine dependence is associated with high rates of 
relapse, contributing to the difficulty of the treatment. A recent study by Brecht and  Herbeck 
(32) tried to shine a light on long term (5 years) abstinence and relapse rates for METH abusers. 
The researchers found that out of a sample of 350 subjects only 13 per cent maintained 
abstinence in this 5-year period, and 61 per cent relapsed during the first year after treatment. 
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This is highly significant, as early rates of relapse, as seen with other drugs of abuse, are usually 
related to an increased effort of maintaining abstinence afterwards. Although, relapse rates 
decrease as abstinence period increases. The authors also identify two main risks of earlier 
relapse: individuals whose parents used drugs before and dealing with METH sales. Initial 
abstinence should be addressed with supportive measures, as Ling et al report (26): healthy 
eating, resting and exercising, with the latter being a promising new approach. These supportive 
measures are subsidiary to pharmacotherapy and to psychosocial and behavioural treatment. 
One should stress that while pharmacotherapy is essentially unsatisfactory, the latter is currently 
the primary strategy regarding METH dependence (33).  
6.2 Pharmacotherapy 
So far, there is no adequate pharmacological treatment specifically for methamphetamine 
dependence (9,10). Guidelines on the subject take into account past and current experience with 
other stimulant’s dependence, and often there is plainly a shortage of proven efficacy studies 
(15). Although, it is noticeable that emphasis on the area is increasing, with more studies being 
developed (34). Pharmacotherapy revolves around the monoamine transporters and 
mechanisms behind their release and reuptake on the synapse, with the goal of re-establishing 
depleted storage vesicles in the CNS and improving dysregulation of the physiologic 
monoamine system. Therefore, the primary aim is to intervene in the dopaminergic reward 
pathways, act in the negative reinforcing effects of withdrawal syndrome and improve 
psychiatric consequences of chronic abuse that impair chances of maintaining abstinence (35).  
There is indeed evidence supporting the usefulness of drugs that release both dopamine and 
serotonin in stimulant abuse dependence (12).  This leads to several drug classes that can and 
are used with variable results, as thorough reviews on the subject inform (34,35): dopamine 
agonists (e.g. methylphenidate, modafinil), antidepressants (bupropion, selective serotonin 
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reuptake inhibitors), antipsychotics (both first and second generation, by antagonism of D2 
receptors), 5-hidroxytriptamine type 3 receptor antagonists (ondansetron), GABAergic agents 
(e.g. baclofen, gabapentine) and eventually cholinesterase inhibitors (rivastigmine). There are 
new strategies being taken in consideration and new drugs under development. M. Brensilver 
et al (35) mention a phosphodiesterase inhibitor used for a long time for the asthma treatment 
in Japan with anti-inflammatory properties discovered in recent years, decreasing METH-
induced glial cell activation. Mirtazapine is another promising new option under investigation; 
cholinergic mechanisms are also being addressed, despite the current lack of evidence in this 
particular area. On the other hand, L. Karila et al (34) bring even more new approaches to the 
table: monoclonal antibodies against methamphetamine, immunization therapies (i.e. vaccines), 
involvement of the endogenous cannabinoid system, agonists of nicotinic receptors and drugs 
from the family of benzoquinolizines. Newly discovered dopamine receptors, namely D3 could 
possibly be an effective therapeutic target in METH dependence (36). 
6.3 Behavioural Therapy 
Being a highly addictive stimulant, methamphetamine dependence can be extremely 
challenging to treat, both to the user as to the healthcare professional (28). A conjoint strategy 
of available therapies seems to work better than a stand-alone one. Apparently, treatment 
responses of METH users are overlapping with those of cocaine users (37). There are essentially 
two behavioural treatment options (26): cognitive-behavioural therapy (CBT) and contingency 
management (CM). CBT comprises several structured sessions led by a therapist pretending to 
raise self-awareness to negative actions or particular situations.  It is proven to have decreased 
stimulant use; however, when compared to CM, this decrease is not as significant. A derivate 
of CBT is the Matrix model, initially developed to treat cocaine dependence (38). Created in 
the early 1980’s, it has suffered various changes according to increasing evidence since then. 
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As with CBT, the therapist with specialized training is the main agent in the whole program, 
establishing a relationship with the patient which serves as a foundation to elicit positive actions 
and behaviour. The main objectives are to interrupt drug use; understand the issues behind 
relapse and addiction; provide support and educate family members; familiarize with self-help 
programs and provide some type of follow-up, as with urine samples (28).  The program lasts 
for a pre-established period of time, originally 16 weeks. There is also proof of significant 
results on follow-up with this model.  
CM in turn began with opiate abusers, and works by strengthening positive behaviours by 
rewarding the patient, thus leading to sustained abstinence. Rewards include vouchers (which 
can be exchanged for food or any other item or service) or even cash incentives. When 
compared to a counselling-only strategy, CM provided less positive urine samples and longer 
periods of abstinence (26).  
Behavioural strategies can be associated to drug court treatment, where the individual is 
requested to remain “clean” for a period of time (no less than one year) and according to a 
number of norms. A recent study concluded that users who attended drug court treatment shown 
higher abstinence, completion and retention rates (39). 
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7. Physical Exercise as a Conjoint Therapy  
The advantages of physical exercise are widely described; there is robust evidence of benefit 
specifically to the CNS (40). Drug abusers seem to be generally sedentary or low active 
individuals with little aerobic capacity (maximum quantity of consumed oxygen by the 
individual during intense exercise, per time unit) (41). Positive outcome has already been 
evaluated for several substances, both legal, as tobacco (42) and alcohol (43) and illegal, as 
cocaine (44), cannabis (45) and MDMA (46).  
Evidence supporting the role of physical exercise on amphetamine and methamphetamine 
dependence is steadily rising. A recent paper by Smith and Lynch  (47) reviews published 
preclinical studies regarding various drugs of abuse, including methamphetamine and ATS. The 
researchers state that aerobic exercise correlates negatively with drug abuse and is associated 
with decreased substance self-administration in all phases of addiction (from acquisition to 
relapse) in rats. The authors conclude by claiming that it is still not entirely clear when should 
exercise be introduced in the overall process for the best possible efficacy and what quantity is 
needed, although ultimately it seems that any amount would have a positive effect, on both 
sexes, with earlier introduction relating to long-term protective effects and significant benefits 
even in sedentary subjects. Another recently published paper concluded that five weeks of 
exercise (swimming protocol) on an animal model (rat), after exposure to amphetamine, led to 
lower relapse rates and attenuated anxiety-like symptoms associated with drug abstinence (21). 
Additionally, it was suggested that exercise promotes modulation of membrane plasticity and 
adjustment of Na+/K+ pump activation.   
Miller et al expand earlier findings on stimulant abuse and exercise. The authors intended to 
found if access to an activity wheel could diminish intravenous d-methamphetamine self-
administration in male rats having previous wheel exercise experience.  It was found that access 
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to an activity wheel simultaneously with the start of intravenous drug administration resulted 
in reduced self-administration of METH (48). There are a few preclinical studies on the sex 
differences regarding exercise and drug intake with relevant results. For example, female rats 
have shown less cocaine self-administration than rats, in programs comprising voluntary wheel 
exercise (49). This could potentially be of concern regarding sex-related preferences and 
characteristics on the practice of exercise.  
Another paper focused on the role of exercise on cardiotoxicity induced by d-amphetamine on 
rats (50). The researchers pointed out extensive cardiotoxicity induced by this stimulant, but 
the exercise group presented less severity in those lesions, with lower markers of oxidative 
stress apparently because of increased reduced glutathione on active subjects, thus providing 
yet another factor adding to its protective role. O’Dell and Marshall give some more insight in 
two very recent papers (20,51). Firstly the authors, along with other researchers, found 
significant improvement in striatal dopamine and cortical serotonin neuron terminals in 
exercised rats after methamphetamine-induced lesions. The authors elaborated a protocol 
consisting in a binge regimen of the drug and a program of 3 weeks of free access to a running-
wheel before and 3 weeks after METH injections (20). Trying to unravel a physiological 
explanation behind these findings, three mechanisms were hypothesized by the same 
researchers (20,51). Firstly, changes induced by exercise before a binge regimen could decrease 
in some way the acute effects of METH, by intervening in the pharmacodynamics and 
biodistribution of the drug. Secondly, physical activity before the methamphetamine injection 
could stimulate the synthesis of protective factors against damaged monoamine nerve terminals, 
for example by intervening with enzyme activity and the oxidative stress system. However the 
researchers found that physical exercise prior but not after a binge regimen failed to protect 
against METH-induced dopaminergic damage in laboratory rats (51). Finally, exercise could 
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promote expression of growth factors that would restore METH-induced lesions. This last 
hypothesis seems the most plausible, and is developed later in this review.  
Also worth mentioning is the fact that exercise needs to happen within certain boundaries to be 
beneficial, as Lynch et  al propose in a comprehensive review: it was demonstrated that intense 
and long-lasting exercise can be harmful instead of helpful, as seen with methamphetamine 
self-administration increasing in rats when exposed to such high-intensity conditions (52). 
The general benefit of exercise in drug abuse only takes effect if the population of drug users 
are willing to take part in such program. In fact, the majority of drug users show interest on the 
practice of exercise (75 per cent according to one study) with some limits that need to be taken 
into account: cost of subscription to a gymnasium and equipment, motivation, available time 
and transport. In another study (53) the majority of individuals claimed walking as a preferred 
method of exercise, with lack of motivation being one of the biggest restrictions to exercising.  
Many ways can be used to increase motivation, such as using a pedometer or cash or other type 
of incentives. However, the limits described by these studies can be actively brought down, as 
exercise can be inexpensive and flexible according to the subpopulation in treatment; also it has 
the advantage of not having the side effects experienced with pharmacotherapy (54). Sex 
differences also dictate whether a specific exercise program is more accepted than other. Men 
usually prefer exercising alone (contrasting with women) and are not as willing to be supervised 
as women. Males also prefer strength training and running while females prefer aerobics and 
yoga. The preventive role of exercise is also of high importance to the addiction process (55). 
For instance, in the teen subpopulation exercise decreases the likelihood of experimenting illicit 
drugs and tobacco use (52). Cognitive impairment seen in substance use disorder probably 
shows improvement with physical exercise, as in a subpopulation of healthy subjects cognitive 
performance is better in the fittest. Chang and colleagues studied the effect of aerobic exercise 
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on cognitive performance in a population of 36 healthy young college students separated into 
three groups of variable fitness; following previous conclusions, the authors stated that 
cognitive performance improved on all groups, with better outcome in the group who practiced 
acute moderate intensity exercise (56).  
Relevant clinical studies have been increasing in the last decade. Dolezal and colleagues appear 
to have been the first to study fitness markers on methamphetamine users, such as heart rate 
variability (HRV) among methamphetamine-dependent users under behavioural therapy (57). 
HRV is a marker of autonomic nervous system function on heart rate, consisting in changes in 
the interval between heart beats over a period of time. The researchers found that 8 weeks of 
exercise improved HRV in these individuals, translating a restitution of the physiologic 
sympathetic and parasympathetic function. Improvement in VO2max has also been noticed in 
these users: the authors point an increase of 24 per cent in this parameter, associated with 
increases in endurance and muscle strength. This supports even further the role of exercise as a 
preventive as well as a treatment option including the management of cardiovascular disorders 
induced by methamphetamine exposure. A pertinent premise brought up by the authors is the 
fact that physical exercise has proven benefit in psychiatric diseases, and can therefore help 
METH users that suffer from such conditions. Another study by Dolezal and colleagues (58) 
with a group of 39 METH-dependent users under residential treatment provided some 
promising findings. Besides improved fitness measures (VO2 max, endurance and strength) on 
exercised individuals, treatment outcome was markedly improved on these users, with decisive 
recommendations: supervised and well-structured exercise programs are a must to achieve 
positive outcomes. The control group, without structured activity, failed to attain significant 
changes in performance and body mass. Two unpublished studies (as of March 2015) by 
Richard A. Rawson and colleagues further develop the influence of exercise on 
methamphetamine dependence. In one of them, the researchers wanted to evaluate the role of a 
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structured exercise program on anxiety and depression on abstinent METH-dependent users 
(59). Findings were positively similar to those described before; individuals who took part in 
more exercise sessions showed better improvement of symptoms than the ones who took part 
in a less number of sessions. As shown in previous studies, there was a significant improvement 
on fitness measures among those participating in these exercise sessions. Despite this optimistic 
outcome, the authors state some limitations to the study: only users under residential treatment 
constituted the sample; therefore the same conclusions may not be seen in outpatient care or 
users who do not seek help at all. Also, the diagnostic of psychiatric disorder (anxiety and 
depression) did not take into account the DSM-IV reference textbook. A second study by 
Rawson et al (60) also concerned an 8-week exercise program for METH-dependent users 
under residential treatment focusing on the efficacy of this program as a potential therapy. The 
population of users was subsequently divided in several severity groups according to days of 
drug use in the past month. The low severity group (< 18 days) showed lower relapse rates 
either at one or three months after discharge of the exercise program. Users who participated in 
more sessions also maintained longer abstinence at follow-up. Sustained abstinence was seen 
in users who reportedly continued exercise at one-month follow-up, more so than users who 
did not report pursuing any exercise activity after discharge. 
Despite the need for more studies (61), with an ever-growing body of evidence for the past few 
years it is rather safe to assume that exercise as a conjoint therapy would probably bring higher 
efficacy to the overall treatment of substance use disorder (43). Additionally it seems plausible 
that well-designed exercise programs aimed at specific subpopulations of users would translate 
into higher adherence and better results. Overall, table 1 highlights the beneficial outcomes 
from physical exercise in drug users including METH users.  
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Table 1. Evidence of physical exercise on substance use disorder 
 
Reference Sample Type of Exercise Duration Drug of Abuse Outcome 
Weinstock et al. 
(2008) (62) 
45 exercisers 
142 non-exercisers 
(n=187, all under 
contingency management 
treatment) 
User self-selected activities thus 
classifying them as exercisers (e.g. 
planning workout routine, basketball, 
swimming, jogging) or non-exercisers 
(paying rent, attending doctor’s 
appointment) 
12 weeks Alcohol, cocaine 
and opioids 
25% completed at least one 
activity; exercisers had longer 
abstinence periods 
Brown et al. 
(2010) (54) 
Cohort of 16 previously 
sedentary drug-dependent 
users, not taking any 
medication that could 
interfere with the results 
(n=16) 
Supervised aerobic exercise program in a 
treadmill started at 20 minutes and 
increasing to 40 during the 12-week 
period; moderate intensity defined by 55-
69% age-predicted maximal heart rate. 
There were also group sessions (15-20 
minutes of duration) and exercise outside 
the facility was promoted 
12 weeks Alcohol, cocaine, 
marijuana, 
opioids, sedatives 
Almost 60% completed all 12 
weeks. 66,7% had not relapse 
at the end of the program; ↑ 
metabolic equivalents; ↓ body 
fat and body mass index 
Dolezal et al. 
(2013) (58) 
29 users finished the 
proposed program, resulting 
in a 74% adherence rate; 15 
elements in the exercise 
group and 14 in a health 
education group with no 
exercise 
(n=39 individuals) 
Endurance training: first 3 weeks jogging 
and/or walking on treadmill during 30 
minutes, at intensity based on heart rate; 
the subsequent 5 weeks had increasing 
intensity 
Resistance training: after the endurance 
training session; progressive circuit-type 
program with selectorized machines and/or 
dumbbell training 
3 days /week, 
8 weeks 
Methamphetamine Improvement of VO2max (↑21%) 
as well as muscle strength and 
endurance. Reduced percent 
relative body fat (↓15%); 
reduced fat weight (↓18%) 
Flemmen et al. 
(2014) (41) 
12 substance-dependent 
users in the training group; 
12 in the control group with 
conventional rehabilitation 
treatment 
(n=24, all in a clinic at the 
time of inclusion) 
Treadmill interval training in 4x4 minutes 
at 90-95% of maximal heart rate (high 
intensity) 
3 days/week,  
8 weeks 
Not specified 3 users in the training group 
and 5 users in the control group 
dropped out. Aerobic power at 
baseline was lower than on the 
average population.  
Improvement of VO2max 
(↑15%) and in depression was 
apparent on the training group 
Dolezal et al. 
(2014) (57) 
28 users under residential 
treatment divided into two 
subgroups of 14 elements, 
one subjected to exercise 
intervention and the other 
Supervised endurance and resistance 
training (1-repetition maximum and 85% 
of 1-repetition maximum for chest and 
legs) 
8 weeks Methamphetamine HRV was reduced in recently 
abstinent users; after the 8-
week period HRV markedly 
increased, VO2max increased by 
24%, muscle strength and 
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took part in health education 
sessions; these were 
compared to 22  age-
matched, drug-free, 
sedentary controls 
(n=50, all males) 
endurance for upper and lower 
body also raised 
Rawson et al. 
(Not yet 
published) (59) 
135 dependent-users under 
residential treatment were 
randomly assigned to an 
exercise (69 users) and a 
health education group 
(consisting in 24 1-hour 
sessions given by a trained 
health-educator) (66 users) 
Endurance (30 minutes on a treadmill) 
followed by resistance (15 minutes of 
weight training) 
3 days/week,  
8 weeks 
Methamphetamine Significantly reduced 
depression and anxiety 
symptom scores (according to 
Beck scales) 
Rawson et al. 
(Not yet 
published) (60) 
135 dependent-users under 
residential treatment were 
randomly assigned to an 
exercise (69 users) and a 
health education group 
(consisting in 24 1-hour 
sessions given by a trained 
health-educator) (66 users) 
Endurance (30 minutes on a treadmill) 
followed by resistance (15 minutes of 
weight training) 
3 days/week,  
8 weeks 
Methamphetamine Median of attendance = 16 
sessions. Better treatment 
compliance and continued 
exercise after the proposed 
program resulted in longer 
abstinence and lower relapse 
rates; fewer exercise group 
users had positive samples for 
METH use at 1-month and 3-
months follow-up, although 
these findings were not 
statistically significant 
34 
 
8. Neurobiology of Exercise on Drug Abuse 
 
As stated earlier, benefits of physical exercise extend to the CNS. In fact, exercise has 
neuroprotective and neurogenerative effects, via expression of genes and subsequently growth 
factors and neurotrophins that prevent neuron injury (in several brain structures such as the 
hippocampus and striatum) and trigger the development of new cells (40). Neurotrophins 
include the brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and glial cell 
line-derived neurotrophic factor (GDNF) which are increased by physical activity (40,51). 
BDNF regulates synaptic plasticity and has some influence on the process of addiction. During 
abstinence its levels rise in mesolimbic structures of the brain following a nadir, stimulating 
drug-seeking behaviour. With exercise, expression of the BDNF gene increases and epigenetic 
mechanisms take action (via acetylation of histone 3 and decreased methylation in the promoter 
IV region of the BDNF gene), thus offsetting the initial decrease in BDNF during early 
withdrawal seen in the reward pathways (47,52). It is suggested that exercise could prevent 
BDNF expression seen in abstinence, thus suppressing drug-seeking behaviour (52). Its effects 
have been studied in alcohol, cocaine and METH users, suggesting it could be a potential 
abstinence biomarker (63). GDNF also increases in exercised animal models, and seems to 
provide a positive effect on striatum recovery after methamphetamine-induced neurotoxicity, 
as seen by raised dopamine levels after injection of this neurotrophic factor in the striatum of 
rats (51). 
As mentioned before, dopamine increase in the nucleus accumbens seems to be one of the main 
mechanisms leading to addiction. Thus, exercise can act as a healthy positive reinforcer. A 
review by Lynch et al thoroughly describes the ways exercise interferes with the reward 
pathways (52). Chronic exercise elevates tyrosine hydroxylase levels (64), increasing dopamine 
in many CNS regions; preclinical studies show activation of dopamine neurons in the VTA and 
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higher levels of dopamine in the nucleus accumbens in animals submitted to wheel running; it 
also increases levels of ΔFosB (which plays a predominant role in the development of 
addiction) and upregulates D1 receptors and D2 receptors (65). The increase in both dopamine 
receptors (D1 and D2) might be beneficial to chronic METH users by restoring unbalanced 
density of these receptors. Also, expression of DAT is decreased in the midbrain of exercised 
subjects, which leads to higher dopamine availability in the synapse, further supporting physical 
exercise as an alternative positive reinforcer (64).  
Other catecholamines also take part in the overall process of addiction. Norepinephrine is 
crucial in the relapse phase after abstinence; exercise manages to decrease norepinephrine levels 
in the frontal cortex. Glutamate is a modulating agent in drug-seeking behaviour and relapse 
and decreases with chronic drug use. Exercise brings its concentration back to normal, as seen 
with ischemia models, similar to the conditions seen in chronic drug abuse (52). The opioid 
system comprising three types of receptors (delta, kappa and mu) and opioid peptides 
(endorphins, enkephalins, dynorphins) are ubiquitous in the CNS. Endogenous opioids increase 
with physical exercise improving mood states, and there is evidence of diminishing exogenous 
opioids use after physical activity (47). For instance, opioid neurons and receptors are present 
in the arcuate nucleus and project to several regions, from the limbic system and basal ganglia 
to the brainstem, specifically VTA (66). This system revolves around the sense of pleasure 
(hedonics) among others, which constitutes a vital part of addiction and reward, and is 
intimately intertwined with dopamine release in the CNS, as opioid receptors (delta) are 
overexpressed by exercise thus inducing dopamine release in the nucleus accumbens (64,67). 
As described earlier, METH abuse leads to serious cardiovascular impairment. In addition, it is 
capable of disrupting the blood-brain barrier, mainly at a cortical and hippocampal level, via 
increased production of reactive oxidative species, leading to altered permeability of the barrier. 
One recent study by Toborek et al (68) verified that physical exercise did offer protection 
36 
 
against this severe damage to the blood-brain barrier in mice injected with METH. Non-
exercised subjects presented lower levels of glutathione in the brain capillaries whilst exercised 
subjects had marginally higher base levels but showed signs of marked improvement after 
METH injection, by raising antioxidant capacity of these capillaries under such circumstances. 
The authors also confirmed previous findings of reduced tight junction protein (e.g. occludin, 
claudin-5 and ZO-1) expression after methamphetamine administration, which explains the 
disrupted barrier and posterior inflammatory response in the brain on these subjects. On the 
same study it was shown that exercise did lessen those changes. Also, it was demonstrated that 
a transcription factor that triggers antioxidant mechanisms (Nrf-2) is overexpressed by physical 
exercise 
Neurogenesis and gliogenesis in the hippocampus is promoted by aerobic exercise. This is 
relevant because reductions of hippocampal neurogenesis are associated with increased drug 
self-administration. It also increases gliogenesis in the prefrontal cortex of rats, which has major 
influence on relapse and drug abuse (47). A study correlating both exercise and METH 
aggression to the prefrontal cortex concluded that the quantity of practised exercise is not as 
important as actually being physically active vs not being active on medial prefrontal cortex 
plasticity; the same study ends by suggesting that voluntary exercise may therefore reverse 
reduction of gliogenesis in chronic METH users (22).   
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Conclusion 
To this date there is no pharmacological treatment directed specifically to methamphetamine 
dependence, thus relying on general drugs used in other dependence treatments and on 
behavioural therapies, with modest outcomes. Physical exercise has been studied as a conjoint 
therapy in other substance dependences for some time now, with overall positive feedback on 
sustained abstinence, as seen with tobacco, alcohol, cannabis and cocaine use. Regarding 
methamphetamine, only in the past few years pertinent preclinical and clinical studies have 
been conducted addressing this drug specifically. Overall, there were great improvements 
demonstrated in active users, with better fitness measures, lower relapse rates and sustained 
abstinence when compared to non-exercised individuals. Further studies are profoundly needed, 
to confirm reproducibility of previous findings: stablish the most efficient exercise program, 
attending to sex, age and mental consequences of chronic use (there are significant differences 
among men and women drug users), namely duration, intensity (it appears moderate intensity 
exercise is the best to begin with), type (no studies focus on anaerobic exercise vs aerobic, with 
positive findings related predominantly to aerobic programs) and need of supervision 
(structured programs apparently have better outcomes) and association with current treatments 
(most clinical studies happen under residential treatment). 
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